The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia

Background: Chronic Myeloid Leukemia’s (CML) treatment was optimized since the development of tyrosine kinase inhibitors (TKI) and an increased overall survival during TKI was noticed. During the TKI era, protocols for assessing response and resistance to treatment were developed. Additional chromos...

Descripción completa

Detalles Bibliográficos
Autores principales: Crisan, AM, Coriu, D, Arion, C, Colita, A, Jardan, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2015
Materias:
Case Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656961/
https://www.ncbi.nlm.nih.gov/pubmed/26664479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656961/
https://www.ncbi.nlm.nih.gov/pubmed/26664479

Ejemplares similares